NCT00459862View on ClinicalTrials.gov

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2013

Conditions
Advanced Malignant MesotheliomaLocalized Malignant MesotheliomaRecurrent Malignant Mesothelioma
Interventions
OTHER

laboratory biomarker analysis

Correlative study

DRUG

pazopanib hydrochloride

Given orally

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00459862 - Pazopanib in Treating Patients With Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter